BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 32417411)

  • 1. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
    Yin L; Xue J; Li R; Zhou L; Deng L; Chen L; Zhang Y; Li Y; Zhang X; Xiu W; Tong R; Gong Y; Huang M; Xu Y; Zhu J; Yu M; Li M; Lan J; Wang J; Mo X; Wei Y; Niedermann G; Lu Y
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):212-224. PubMed ID: 32417411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses.
    Caetano MS; Younes AI; Barsoumian HB; Quigley M; Menon H; Gao C; Spires T; Reilly TP; Cadena AP; Cushman TR; Schoenhals JE; Li A; Nguyen QN; Cortez MA; Welsh JW
    Clin Cancer Res; 2019 Dec; 25(24):7576-7584. PubMed ID: 31540976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
    Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
    J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination low-dose cyclophosphamide with check-point blockade and ionizing radiation promote an abscopal effect in mouse models of melanoma.
    Luo X; Zeng M
    J Cancer Res Ther; 2024 Apr; 20(2):718-725. PubMed ID: 38687945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.
    Onyshchenko K; Luo R; Rao X; Zhang X; Gaedicke S; Grosu AL; Firat E; Niedermann G
    Theranostics; 2024; 14(6):2573-2588. PubMed ID: 38646638
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects.
    Schoenhals JE; Cushman TR; Barsoumian HB; Li A; Cadena AP; Niknam S; Younes AI; Caetano MDS; Cortez MA; Welsh JW
    Front Immunol; 2018; 9():2170. PubMed ID: 30294332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Effects of Radiation Therapy-Induced Abscopal Responses in Patients with Advanced Lung Cancer.
    D'Andrea MA; Reddy GK
    Oncology; 2021; 99(1):1-14. PubMed ID: 33221794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
    Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
    BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.
    Iocolano M; Wild AT; Hannum M; Zhang Z; Simone CB; Gelblum D; Wu AJ; Rimner A; Shepherd AF
    Acta Oncol; 2020 Feb; 59(2):164-170. PubMed ID: 31608751
    [No Abstract]   [Full Text] [Related]  

  • 11. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials.
    Chen D; Menon H; Verma V; Guo C; Ramapriyan R; Barsoumian H; Younes A; Hu Y; Wasley M; Cortez MA; Welsh J
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31996395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
    Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
    [No Abstract]   [Full Text] [Related]  

  • 13. Ablative Hypofractionated Radiation Therapy Enhances Non-Small Cell Lung Cancer Cell Killing via Preferential Stimulation of Necroptosis In Vitro and In Vivo.
    Wang HH; Wu ZQ; Qian D; Zaorsky NG; Qiu MH; Cheng JJ; Jiang C; Wang J; Zeng XL; Liu CL; Tian LJ; Ying GG; Meng MB; Hao XS; Yuan ZY
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):49-62. PubMed ID: 29619976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer.
    Ji D; Song C; Li Y; Xia J; Wu Y; Jia J; Cui X; Yu S; Gu J
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33106387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
    Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
    Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity.
    Chen D; Barsoumian HB; Fischer G; Yang L; Verma V; Younes AI; Hu Y; Masropour F; Klein K; Vellano C; Marszalek J; Davies M; Cortez MA; Welsh J
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model.
    Song HN; Jin H; Kim JH; Ha IB; Kang KM; Choi HS; Jeong HJ; Kim MY; Kim HJ; Jeong BK
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.
    Pierini S; Mishra A; Perales-Linares R; Uribe-Herranz M; Beghi S; Giglio A; Pustylnikov S; Costabile F; Rafail S; Amici A; Facciponte JG; Koumenis C; Facciabene A
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33563772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects.
    Hu Y; Paris S; Barsoumian H; Abana CO; He K; Wasley M; Younes AI; Masrorpour F; Chen D; Yang L; Dunn JD; Zhang J; Gandhi S; Nguyen QN; Cortez MA; Welsh J
    Int J Radiat Oncol Biol Phys; 2021 Nov; 111(3):647-657. PubMed ID: 34242713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.